Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma
Conditions: Oral Cancer; VEGFR2 Inhibitor; Programmed Cell Death 1 Inhibitor; Inductive Therapy Interventions: Drug: Camrelizumab; Drug: Apatinib; Procedure: Radical surgery; Radiation: Post-operative radiotherapy/chemoradiotherapy Sponsor: Shanghai Jiao Tong University School of Medicine Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Oral Cancer | Research | Skin Cancer | Squamous Cell Carcinoma